Pharma Professionals Converged to Share Insights and Advance Industry Progress
The 93rd API China, China’s first and longest-running pharmaceutical ingredients exhibition, took place from 12–14 November 2025 at the Chongqing International Exposition Center (CQEXPO). The industry-defining landmark event for the global pharmaceutical and healthcare industry reaffirmed its status as Asia’s premier trade exhibition forging the biophrama landscape. API China connects China’s pharma innovations with global markets, attracting industry professionals from over 5,000 finished drug manufacturers to its show floor. As the global healthcare landscape continues to evolve, API China remains at the forefront, driving innovation and shaping the future of healthcare.
API China, Asia's largest pharma and healthcare exhibition, brought together more than 30,000 industry professionals and 1,200+ exhibitors granting access to a uniquely diverse industry network and magnificent perspective to uncover new opportunities across China’s fast-evolving pharmaceutical arena.
A testament to the pharmaceutical industry's resilience and innovation, API China 2025 featured the latest innovations in Active Pharmaceutical Ingredients (APIs), biopharma, healthcare technology, pharma machinery and more. The event set a new benchmark for pharma exhibitions in Asia by connecting industry leaders, showcasing groundbreaking technologies, and fostering collaborations, and cementing its role as a pivotal platform for collaboration and business growth.
A One-Stop Centralized Hub for Industry Leaders and Innovators:
API China 2025 served as a premier platform for industry stakeholders and key opinion leaders, uniting decision-makers, manufacturers, and innovators across the global pharmaceutical supply chain. The event offered unparalleled opportunities for networking and collaboration, enabling attendees to contribute to shaping the future of the industry.
Innovation and cutting-edge advancements were central themes at the event, showcasing the latest developments in the pharmaceutical sector. Participants explored breakthroughs in APIs, biopharma development, fine chemicals, excipients, and next-generation drug delivery systems, spotlighting API China's role as a premier platform for sourcing, networking, and shaping the future of pharma and healthcare.
Reed Sinopharm Exhibition’s spokesperson quoted, “API China has long been the cornerstone of China’s pharmaceutical ecosystem. At the 93rd edition, we saw vibrant exchanges, collaborations, and innovations across APIs, excipients, packaging, biopharma, and manufacturing technologies — underscoring the show’s role as a catalyst for industry progress.”
The forum collaborated with a number of domestic and international industry associations, including the China National Pharmaceutical Industry Association (CNPIA), China Pharmaceutical Packaging Association (CPPA), International Pharmaceutical Excipients Council China (IPEC China), and the Chongqing Industry Association. Together, they focused on key themes like pharmaceutical R&D, quality control, production processes, environmental protection & safety, and compliance. These collaborations emphasized the singnificance of public-private partnerships to elevate the industry potentials under connected framework.
Beyond active pharmaceutical ingredients (APIs), the event covers all aspects of pharmaceutical manufacturing. Built on four interconnected pillars, API China focusesed on advanced APIs, biologics, and contract manufacturing; Pharmex, dedicated to excipients; Pharmpack, which highlights intelligent and sustainable pharmaceutical packaging; and Sinophex, which specializes in machinery, cleanroom, and laboratory technologies.
Knowledge-Driven Forums, Conferences and Workshops
API China 2025 featured a series of technical summits, academic workshops, and industry conferences designed for attendees to gain a comprehensive perspective of latest policy trends, global regulations, and advancements in biopharma R&D. These sessions provided a platform for thought leaders to address key issues, including regulatory updates, sustainability in pharmaceutical manufacturing, and the development of Traditional Chinese Medicine (TCM). Participants gained valuable insights into the evolving healthcare and drug manufacturing landscape, preparing them to navigate the industry's challenges and opportunities. Over 100 industry leaders, renowned experts, and executives from leading pharmaceutical companies shared their expertise and experiences at the event.
Featuring technical forums, seminars, and cutting-edge advancements, API China serves as a platform for sharing knowledge, fostering cooperation, and connecting exhibitors with international markets.
Interestingly, a series of forums and technical conferences exclusively covered critical aspects across China's pharmaceutical value chain. During the convention, more than 30 conferences and forums were held, addressing key topics in the domestic and international pharmaceutical industry, including policy trends, data insights, global market dynamics, and strategic collaborations.
Alongside the exhibition floor, API China features a programme of forums and conferences.
Forums such as the IPEC Federation China Excipient Conference, brought together regulators, experts, and manufacturers to explore GMP standards, regulatory frameworks, and innovations in excipients across various countries. The IPEC Federation China Excipient Conference, was co-organised by IPEC China and RSE. Launched in 2012, the conference provides a platform for excipient-focused dialogue, convening regulators, experts, and manufacturers to exchange perspectives on GMP, regulatory reforms, technological advances, and the evolving role of excipients in drug development.
In addition, API China hosted the 40th China Pharmaceutical Industry Market Information Conference, which brought together policymakers and industry leaders to share data-driven insights on market trends and policy direction.
New thematic sessions explored nutritional health opportunities for pharma enterprises, innovation in the pet medicine supply chain, and technological progress in chemical and process safety, alongside forward-looking exchanges on pharma export strategies, eCTD implementation, and intelligent process design.
Furthur, 93rd API China event featured key sessions, including the China Pharmaceutical Engineering Conference, China API Market Report, and China Pharmaceutical Industry Production and Sales Briefing. Collectively, these sessions reinforced API China’s role as a vital platform for knowledge sharing and cross-disciplinary collaboration — driving the continuous advancement of China’s pharmaceutical and biopharmaceutical sectors.
Furthurmore, continues discussions included regulatory updates, manufacturing excellence, green development, and emerging therapeutic areas, reflecting the industry's commitment to quality, innovation, and sustainable growth. Key discussions explored generic drug manufacturing efficiency, pharmaceutical excipient GMP compliance, lipid-based drug delivery, and advancements in TCM quality, alongside the green transformation of pharmaceutical engineering.
“Partnering with API China allows us to engage the broader pharmaceutical ecosystem in meaningful dialogue,” said Ms. Cloris Tian, Chairperson of IPEC China. “It creates a valuable opportunity for local and global excipient experts, users, manufacturers, and other stakeholders to exchange insights on the latest regulatory developments ssin China and worldwide, align on quality expectations and best practices, and strengthen collaboration across markets. By curating content around the industry’s most pressing needs, we aim to advance our shared goal of ensuring the quality and safety of pharmaceutical excipients globally.”
B2B Matchmaking and Networking Opportunities:
API China 2025 emphasized business growth through exclusive B2B matchmaking sessions. Reflecting the exhibition’s growing international relevance, delegations and visitors from more than 20 countries and regions joined the event to explore collaboration opportunities. Discussions around cross-border cooperation, quality management, and technology transfer highlighted API China’s continued importance as a bridge between China’s domestic industry and the global pharmaceutical community.
Exclusive opportunities to explore groundbreaking biopharma and API innovations, networking with representatives from China’s top 100 pharmaceutical companies, and gaining comprehensive insights into pharmaceutical manufacturing, packaging, and machinery made API China 2025 an exceptional event.
Attendees gained valuable insights through matchmaking sessions that connected them with leading pharmaceutical companies, contract manufacturing service providers (CROs, CMOs, and CDMOs), and research collaborators. These sessions played a key role in fostering partnerships, driving innovation, and creating new business opportunities. Participants also engaged with industry experts, gaining actionable knowledge to navigate the dynamic pharmaceutical landscape and explore growth avenues.
Visitors also enjoyed free online registration and e-badge access, priority entry to conferences, and early registration benefits, making it easier than ever to participate in this premier industry event.
The 93rd API China has played a significant role in the Chinese pharmaceutical market for over 50 years, serving as a vital platform for global pharmaceutical brands to enter and expand in China. The event focuses on supporting innovation across the entire pharmaceutical supply chain, encompassing products and technologies from R&D to production. Participating companies represent diverse sectors, including Active Pharmaceutical Ingredients (APIs), intermediates, natural products, pharmaceutical excipients, packaging, equipment, biopharmaceuticals, and outsourcing services such as CRO, CDMO, and CMO. The exhibition showcases the latest advancements and technologies from China's pharmaceutical industry.
API China 2025 provided a comprehensive display of the latest advancements in the pharmaceutical industry while connecting attendees with key decision-makers, manufacturers, and innovators driving the future of global pharmaceuticals and healthcare. The exhibition covered the entire pharmaceutical supply chain, featuring APIs, biopharma innovations, contract manufacturing, chemical intermediates, and pharma packaging solutions. Strong participation underscored sustained confidence in China’s evolving pharmaceutical landscape. Exhibitors and buyers connected across the supply chain to identify solutions, strengthen networks, and explore new opportunities — reinforcing API China’s role as a trusted marketplace where business relationships take shape.
The lasting impact of API China 2025 on the Pharma Industry
API China 2025 was more than just an exhibition; it was a strategic gateway to China’s rapidly expanding pharmaceutical market. With comprehensive coverage of pharma manufacturing, packaging, and machinery, the exhibition underscored its role as a vital business platform for API manufacturers, biotech companies, and healthcare innovators.
The 93rd edition provided a unique opportunity for cutting-edge technologies, sustainable solutions, and global industry trends that helped stakeholders connect, innovate, and advance the pharmaceutical supply chain.
API China remains at the forefront of the pharmaceutical industry, driving progress by highlighting breakthrough technologies, offering cutting-edge insights, and fostering valuable partnerships within China’s rapidly evolving pharmaceutical and biopharmaceutical sectors. At the 93rd API China, pharmaceutical ingredients and manufacturing, brought together top innovators, decision-makers, and industry leaders from across the global pharmaceutical supply chain. As the flagship event for pharmaceutical raw materials, intermediates, packaging, and equipment, API China 2025 will present the latest technologies, sustainable solutions, and global industry trends.
Looking Ahead on the Horizon
The 94ᵗʰ installment of API China will return to Shanghai from 13-15 May 2026, continuing its mission to connect ideas, technologies, and partnerships that drive pharmaceutical progress.
With more than 90 successful editions to date, API China remains the proven platform where business opportunities in China’s pharmaceutical industry take shape. Spanning more than four decades, the show remains the cornerstone of China’s pharmaceutical ecosystem, highlighting key industry themes including manufacturing efficiency, quality and regulatory excellence, therapeutic and formulation innovation, sustainable development, biopharma, and digitalization across the pharmaceutical value chain.
